Diabetic Retinopathy

Riverside Diabetes was part of the clinical research effort that led to the regulatory approval of IDx-DR, an AI-based diagnostic system for the autonomous detection of diabetic retinopathy developed by Digital Diagnostics.

IDx-DR is the first autonomous, AI-based diagnostic system authorized for commercialization by the FDA. More than 30 million Americans have diabetes, and an estimated 24,000 lose vision each year from diabetic retinopathy, a complication of diabetes. If diabetic retinopathy is caught in its early stages, vision loss and blindness are almost entirely preventable.

IDx-DR can be used to provide an immediate, reliable assessment for diabetic retinopathy, including macular edema, during a routine office visit. The exam is performed on site in minutes and produces a diagnostic interpretation and associated report, including care instructions that are aligned with the American Academy of Ophthalmology preferred practice pattern for diabetic retinopathy.

As an autonomous, AI-based system, IDx-DR is unique in that it makes an assessment without the need for a clinician to also interpret the image or results, making it usable by health care providers in clinical disciplines other than ophthalmology.

IDx-DR is intended for use by health care providers to automatically detect more than mild diabetic retinopathy (mtmDR) in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.